Led by Gordon Mills, chair of systems biology at the University of Texas MD Anderson Cancer Center, a group of researchers is developing a database containing proteomic characterizations of thousands of cancer patient samples and cell lines.
A recent investigation by the National Cancer Institute's Cancer Genome Atlas consortium into the genetic underpinnings of breast tumors also offers a glimpse of the benefits of including proteomic data in such analyses.
Researchers from the MD Anderson Cancer Center have identified PARP1 and several other proteins as potential drug targets in small cell lung cancer using reverse-phase protein arrays to compare proteins in small cell and non-small cell lung cancer cell lines.
With a recent market development agreement with clinical trial services company Med Fusion, Theranostics Health continues its push to bring its first protein diagnostic product to market in early 2013.
Molecular diagnostics firm Theranostics Health plans to commercially launch the first of its TheraLink diagnostic assays by the first quarter of next year, company officials told ProteoMonitor this week.